Sterling C. Johnson

Sterling C. Johnson

Auto-generated profile, based on publicly available information

Sterling C. Johnson

Wisconsin Alzheimer’s Disease Research Center, School of Medicine and Public Health, University of Wisconsin, Madison, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 October 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
SNScott C. Neu
Scott C. Neu
JPJudy Pa
Judy Pa
WKWalter Kukull
Walter Kukull
DBDuane Beekly
Duane Beekly
AKAmanda Kuzma
Amanda Kuzma
ATArthur W. Toga
Arthur W. Toga
For nearly 20 years, the prevalent view has been that women who carry copies of the ε4 allele of the apolipoprotein E (APOE) gene have a greater risk of developing Alzheimer disease (AD) than men with the same number of copies.1 The ε4 allele is the main genetic risk factor for late-onset Alzheimer disease (AD),2 and sex-based differences in AD risk have important implications for treatment trials, diagnostics, and therapeutics.3 Additionally, the sex-dependent relationship between APOE and mild cognitive impairment (MCI), which is often a transitional phase from cognitively normal (NL) aging to dementia,4 is unclear. Studies are in general agreement that the APOE ε4 allele is a risk factor for developing MCI,5-11 but there is controversy as to whether it increases10,12-14 or does not increase9,11,15,16 the risks of transitioning from MCI to AD or dementia. The 3 most common alleles of the APOE gene are ε2, ε3, and ε4; whereas carrying the ε4 allele increases one’s risk of developing AD, the ε2 allele conversely has a putative protective effect that is associated with longevity and a lower AD risk.17

22 December 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
NVNicholas M. Vogt
Nicholas M. Vogt
KRKymberleigh A. Romano
Kymberleigh A. Romano
BDBurcu F. Darst
Burcu F. Darst
CECorinne D Engelman
Corinne D Engelman
SJSterling C. Johnson
Sterling C. Johnson
FRFederico E. Rey
Federico E. Rey
Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s disease (AD), such as metabolic, cardiovascular, and cerebrovascular disease. In this study, we tested whether TMAO is linked to AD by examining TMAO levels in cerebrospinal fluid (CSF) collected from a large sample (n = 410) of individuals with Alzheimer’s clinical syndrome (n = 40), individuals with mild cognitive impairment (MCI) (n = 35), and cognitively-unimpaired individuals (n = 335). Linear regression analyses were used to determine differences in CSF TMAO between groups (controlling for age, sex, and APOE ε4 genotype), as well as to determine relationships between CSF TMAO and CSF biomarkers of AD (phosphorylated tau and beta-amyloid) and neuronal degeneration (total tau, neurogranin, and neurofilament light chain protein). CSF TMAO is higher in individuals with MCI and AD dementia compared to cognitively-unimpaired individuals, and elevated CSF TMAO is associated with biomarkers of AD pathology (phosphorylated tau and phosphorylated tau/Aβ42) and neuronal degeneration (total tau and neurofilament light chain protein). These findings provide additional insight into gut microbial involvement in AD and add to the growing understanding of the gut–brain axis.

1 December 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NANicholas J. Ashton
Nicholas J. Ashton
SJShorena Janelidze
Shorena Janelidze
NMNiklas Mattsson-Carlgren
Niklas Mattsson-Carlgren
ABAlexa Pichet Binette
Alexa Pichet Binette
OSOlof Strandberg
Olof Strandberg
OHOskar Hansson
Oskar Hansson
Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the identification of AD pathology or monitoring of disease progression. Blood biomarkers that correlate with changes in cognition and atrophy during the course of the disease could be used in clinical trials to identify successful interventions and thereby accelerate the development of efficient therapies. When disease-modifying treatments become approved for use, efficient blood-based biomarkers might also inform on treatment implementation and management in clinical practice. In the BioFINDER-1 cohort, plasma phosphorylated (p)-tau231 and amyloid-β42/40 ratio were more changed at lower thresholds of amyloid pathology. Longitudinally, however, only p-tau217 demonstrated marked amyloid-dependent changes over 4–6 years in both preclinical and symptomatic stages of the disease, with no such changes observed in p-tau231, p-tau181, amyloid-β42/40, glial acidic fibrillary protein or neurofilament light. Only longitudinal increases of p-tau217 were also associated with clinical deterioration and brain atrophy in preclinical AD. The selective longitudinal increase of p-tau217 and its associations with cognitive decline and atrophy was confirmed in an independent cohort (Wisconsin Registry for Alzheimer’s Prevention). These findings support the differential association of plasma biomarkers with disease development and strongly highlight p-tau217 as a surrogate marker of disease progression in preclinical and prodromal AD, with impact for the development of new disease-modifying treatments.

6 May 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JFJuan Fortea
Juan Fortea
JPJordi Pegueroles
Jordi Pegueroles
DADaniel Alcolea
Daniel Alcolea
OBOlivia Belbin
Olivia Belbin
OIOriol Dols Icardo
Oriol Dols Icardo
VMVíctor Montal
Víctor Montal